Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Deirdre McMenamin"'
Autor:
Miguel Romanello Joaquim, Emma E. Furth, Yong Fan, Hee Kwon Song, Stephen Pickup, Jianbo Cao, Hoon Choi, Mamta Gupta, Quy Cao, Russell Shinohara, Deirdre McMenamin, Cynthia Clendenin, Thomas B. Karasic, Jeffrey Duda, James C. Gee, Peter J. O’Dwyer, Mark A. Rosen, Rong Zhou
Publikováno v:
Cancers, Vol 14, Iss 16, p 4017 (2022)
KPC (KrasG12D:Trp53R172H:Pdx1-Cre) and CKS (KrasG12D:Smad4L/L:Ptf1a-Cre) mice are genetically engineered mouse (GEM) models that capture features of human pancreatic ductal adenocarcinoma (PDAC) and intraductal papillary mucinous neoplasms (IPMN), re
Externí odkaz:
https://doaj.org/article/126c455d27ae451a86fde3cadfa0f99e
Autor:
Jenny A. Greig, Jayme M.L. Nordin, Christine Draper, Deirdre McMenamin, Edward A. Chroscinski, Peter Bell, John T. Gray, Laura K. Richman, James M. Wilson
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 10, Iss , Pp 237-244 (2018)
Liver metabolism disorders are attractive targets for gene therapy, because low vector doses can reverse the buildup of toxic metabolites in the blood. Crigler-Najjar syndrome is an inherited disorder of bilirubin metabolism that is caused by the abs
Externí odkaz:
https://doaj.org/article/0cdfa4f8c1e84e47b68f369400bd39cb
Autor:
Vibhor Gupta, C Linn Cadieux, Deirdre McMenamin, C Angelica Medina-Jaszek, Muhammad Arif, Omua Ahonkhai, Erik Wielechowski, Maryam Taheri, Yan Che, Tamara Goode, Maria P Limberis, Mingyao Li, Douglas M Cerasoli, Anna P Tretiakova, James M Wilson
Publikováno v:
PLoS ONE, Vol 14, Iss 11, p e0225188 (2019)
Rare diseases defined by genetic mutations are classic targets for gene therapy. More recently, researchers expanded the use of gene therapy in non-clinical studies to infectious diseases through the delivery of vectorized antibodies to well-defined
Externí odkaz:
https://doaj.org/article/af3d61c7a5b44e0bb6363de47de712bb
Autor:
James M. Wilson, Mark L. Batshaw, John H. White, Peter Bell, Chenyu Xu, Yang Yang, Yan Che, Hiroki Morizono, Jia Zhang, Deirdre McMenamin, Mingyao Li, Caitlin Latshaw, Camilo Breton, Alexei Saveliev, Lili Wang, Hongwei Yu, Zhenning He
Publikováno v:
Science Advances
AAV- and CRISPR-Cas9–mediated gene targeting in neonatal mice led to clinical benefits in a mouse model of OTC deficiency.
Ornithine transcarbamylase (OTC) deficiency is an X-linked urea cycle disorder associated with high mortality. Although
Ornithine transcarbamylase (OTC) deficiency is an X-linked urea cycle disorder associated with high mortality. Although
Autor:
Dougal Sheridan, Deirdre McMenamin
Publikováno v:
Landscape Research. 44:787-803
Performative analysis of the use of landscape strategies in pre-industrial vernacular architecture indicates that there is more design agency involved in the creation of these environments than con...
Autor:
Laura K. Richman, Jayme M.L. Nordin, Peter Bell, Edward A. Chroscinski, James M. Wilson, Jenny A. Greig, Christine Draper, John T. Gray, Deirdre McMenamin
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 10, Iss, Pp 237-244 (2018)
Molecular Therapy. Methods & Clinical Development
Molecular Therapy. Methods & Clinical Development
Liver metabolism disorders are attractive targets for gene therapy, because low vector doses can reverse the buildup of toxic metabolites in the blood. Crigler-Najjar syndrome is an inherited disorder of bilirubin metabolism that is caused by the abs
Autor:
James M. Wilson, Muhammad Arif, Douglas M. Cerasoli, C. Angelica Medina-Jaszek, Yan Che, Vibhor Gupta, Erik Wielechowski, C Linn Cadieux, Maryam Taheri, Mingyao Li, Tamara Goode, Maria P. Limberis, Anna Tretiakova, Deirdre McMenamin, Omua Ahonkhai
Publikováno v:
PLoS ONE
PLoS ONE, Vol 14, Iss 11, p e0225188 (2019)
PLoS ONE, Vol 14, Iss 11, p e0225188 (2019)
Rare diseases defined by genetic mutations are classic targets for gene therapy. More recently, researchers expanded the use of gene therapy in non-clinical studies to infectious diseases through the delivery of vectorized antibodies to well-defined
Autor:
Scott N. Ashley, Deirdre McMenamin, Christian Hinderer, James M. Wilson, Suryanarayan Somanathan, Maxwell Arias, Christine Draper
Publikováno v:
The Journal of Immunology. 198:4581-4587
CTL responses to the transgene product remain an active area of concern for the gene therapy field. A patient’s underlying genetic mutation may influence the qualitative nature of these potentially destructive T cell responses. Individuals with a m
Autor:
John H. White, Zhenning He, Yan Che, Alexei Saveliev, Yang Yang, James M. Wilson, Caitlin Latshaw, Camilo Breton, Lili Wang, Deirdre McMenamin, Jia Zhang, Mingyao Li
Publikováno v:
Blood. 133(26)
Many genetic diseases, including hemophilia, require long-term therapeutic effects. Despite the initial success of liver-directed adeno-associated virus (AAV) gene therapy for hemophilia in clinical trials, long-term sustained therapeutic effects hav
Autor:
Mark L. Batshaw, Deirdre McMenamin, John H. White, Hongwei Yu, Zhenning He, James M. Wilson, Peter Bell, Chenyu Xu, Hiroki Morizono, Lili Wang, Yang Yang, Kiran Musunuru
Publikováno v:
Nature biotechnology
Many genetic liver diseases in newborns cause repeated, often lethal, metabolic crises. Gene therapy using nonintegrating viruses such as adeno-associated virus (AAV) is not optimal in this setting because the nonintegrating genome is lost as develop